Acute and Persistent Pain in ICU Patients (PAIN-ICU)
Acute and Persistent Pain in Intensive Care Patients
Approximately 20,000 patients are treated in intensive care units (ICU) in Finland annually. During ICU stay many diagnostic and other procedures as well as immobilization and underlying diseases may cause pain. Therefore the incidence of pain in ICU patients can be high. Acute pain may cause several detrimental effects including respiratory distress, tissue hypoxia, immunosuppression and anxiety. After discharge many survivors of critical care have lower health-related quality of life, symptoms of post-traumatic stress disorder or persistent pain.
Only few studies with a focus on acute or persistent pain in ICU patients have been made, hence the incidence and risk factors for ICU-related pain is not very well known. Some of the identified risk factors for persisting pain may be increased age, sepsis or inadequate pain management during ICU stay. Opioids are most often used for analgesics in intensive care. Because they may have several adverse effects the use must be based on validated pain scales. Many factors such as sedation, relaxation or delirium of the patient complicates the management of the pain.
This prospective observational study aims to determine the incidence and risk factors for acute and persistent pain in ICU patients as well as and the use of analgesics during intensive care.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This prospective observational study aims to determine the incidence and risk factors for acute and persistent pain in ICU patients as well as and the use of analgesics during intensive care.
The recruitement process is finished, but the follow-up is on-going. Patients are followed-up by subsequent questionnaires until 5 years after admission to the ICU.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland
- Helsinki University Central Hospital, Meilahti
-
Tampere, Finland
- Tampere University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- not meeting the exclusion criteria
Exclusion Criteria:
- pregnant patients
- age under 18 years
- suffering from significant brain injury
- elective neurosurgical patients
- probable organ donors
- suffering from significant cognitive impairment
- presumed death under 48h
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ICU patients
Over 18-year old intensive care patients, non-interventional prospective observational study
|
Non-interventional
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of acute pain
Time Frame: Through study completion, an average of 3 days
|
Moderate or severe pain (numerical rating scale (NRS) value above 3 / critical pain observatory tool (CPOT) value ≥3) during intensive care
|
Through study completion, an average of 3 days
|
|
Incidence of persistent neuropathic pain using Pain Detect
Time Frame: At intensive care follow up clinic at three months after discharge and thereafter the change in pain annually for 5 years
|
Moderate or severe pain.
|
At intensive care follow up clinic at three months after discharge and thereafter the change in pain annually for 5 years
|
|
Incidence of anxiety affecting persistent pain
Time Frame: At intensive care follow up clinic at three months after discharge and thereafter the change in anxiety annually for 5 years
|
State Trait anxiety Index T (STAI-T)
|
At intensive care follow up clinic at three months after discharge and thereafter the change in anxiety annually for 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Analgesic use
Time Frame: Through study completion, an average of 3 days
|
Analgesics administered during intensive care including indications and dosages
|
Through study completion, an average of 3 days
|
|
Delirium
Time Frame: Through study completion, an average of 3 days
|
Incidence of delirium during intensive care by using Intensive Care Delirium Screening Checklist (ICDSC, scores 0-8) scale, a sum of symptoms equal or above 4 is considered affirmative for delirium
|
Through study completion, an average of 3 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Maija-Liisa Kalliomäki, Tampere University Hospital
- Study Chair: Otto Mäkinen, Tampere University
- Study Chair: Sari Karlsson, Tampere University Hospital
- Study Chair: Simo Varila, Tampere University Hospital
- Study Chair: Minna Peltomaa, Tampere University Hospital
- Study Chair: Karita Koskinen, HUS
- Study Chair: Anna-Maria Kuivalainen, HUS
- Study Chair: Katri Hamunen, HUS Pain Clinic
- Study Chair: Minna Bäcklund, HUS
- Study Chair: Sari Sutinen, HUS
- Study Chair: Leena Pettilä, HUS
- Study Chair: Annika Laukkanen, Töölö Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUS/2779/2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
NCT06638437Not yet recruitingChronic Post-operative Pain | Chronic Postsurgical Pain | Chronic Post-surgical Pain | Chronic Postoperative Pain
-
NCT03119896CompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain Hip
-
NCT07081737Not yet recruitingPain Management | Pain, Chronic | Chronic Pain, Widespread
-
NCT06906211RecruitingChronic Back Pain | Chronic Pain (back / Neck)
-
NCT03249558CompletedChronic Low Back Pain | Chronic Neck Pain
-
NCT05616702RecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back Pain
-
NCT07179016RecruitingJoint Pain | Chronic Knee Pain | Chronic Pain (Back / Neck) | Chronic Pain Management
-
NCT01967342CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to Injury
-
NCT06759675Not yet recruiting
-
NCT07010627Enrolling by invitationChronic Low Back Pain | Chronic Shoulder Pain | Chronic Knee Pain
Clinical Trials on Non-interventional
-
NCT07613593Not yet recruitingChronic Kidney Disease
-
NCT05510908CompletedUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related Malignancy
-
NCT02668341Unknown
-
NCT07215065CompletedHeavy Metal Exposure From Vaping
-
NCT03508258Withdrawn
-
NCT07645391Recruiting
-
NCT07325006RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm
-
NCT07227038RecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast Carcinoma
-
NCT07212491Enrolling by invitationBarrett Esophagus | Esophageal Adenocarcinoma
-
NCT07456436RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System Neoplasm